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Metabolic control is mediated by the dynamic assemblies and function of multiple redox
enzymes. A key element in these assemblies, the P450 oxidoreductase (POR), donates
electrons and selectively activates numerous (>50 in humans and >300 in plants) cyto-
chromes P450 (CYPs) controlling metabolism of drugs, steroids and xenobiotics in humans
and natural product biosynthesis in plants. The mechanisms underlying POR-mediated CYP
metabolism remain poorly understood and to date no ligand binding has been described to
regulate the specificity of POR. Here, using a combination of computational modeling and
functional assays, we identify ligands that dock on POR and bias its specificity towards CYP
redox partners, across mammal and plant kingdom. Single molecule FRET studies reveal
ligand binding to alter POR conformational sampling, which results in biased activation of
metabolic cascades in whole cell assays. We propose the model of biased metabolism, a
mechanism akin to biased signaling of GPCRs, where ligand binding on POR stabilizes dif-
ferent conformational states that are linked to distinct metabolic outcomes. Biased meta-
bolism may allow designing pathway-specific therapeutics or personalized food suppressing
undesired, disease-related, metabolic pathways.
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Dynamic assemblies and function of multiple redox proteinpartners with cytochromes P450 (CYPs) and NADPH-dependent cytochrome P450 oxidoreductase (POR)
orchestrate control of multiple metabolic cascades across
kingdoms1–3. POR transfers electrons to the heme iron of CYPs
and other redox partners selectively activating them4–10. In
plants, the coordinated assembly of POR-CYP complexes in
dynamic metabolons enables on demand in vivo production of
natural products to fend off, counteract or adapt to biotic or
abiotic environmental stress, as recently demonstrated in the crop
plant sorghum1,11. Metabolon formation also regulates parts of
primary metabolism. In humans, POR-CYP assemblies serve to
properly balance the metabolism of drugs, steroids, fatty acids,
xenobiotics, and bio-active plant natural products in foods2,4.
Mutations in human POR alter POR specificity towards activa-
tion of CYPs leading to severe disorders with multiple clinical
manifestations varying from skeletal malformations with cra-
niosynostosis (similar to Antley-Bixler Syndrome) to ambiguous
genitalia and disorder of sexual development, amongst
others3,4,12–14. Exploiting this regulatory layer is central for the
treatment of metabolic disorder and tailored biosynthesis of
natural products, however the mechanisms regulating, or biasing,
POR specificity towards CYPs are not well understood.
Biased specificity has historically been observed to underlie
function of signaling hubs like the G protein-coupled receptors
(GPCRs). Docking of structurally diverse ligands biases GPCR
conformational sampling, stabilizing distinct conformational
states and thus the corresponding signaling pathways, a phe-
nomenon called biased agonism15–17. POR acts as a metabolic
hub: its conformational sampling and specificity towards CYPs is
dependent on regulatory cues5,6,18 and mutations4,19–21 indicat-
ing that POR specificity of activating metabolic cascades may
operate via mechanisms akin to biased agonism. However, to date
no small molecules are known to target metabolic hubs like POR
and allosterically control downstream metabolic pathways.
Here, we show that the specificity of POR towards diverse
electron acceptors can be tuned by small molecules. We
demonstrate using computational modeling that the small
molecules serve as ligands binding on POR. Comparative in vitro
activity assays on a set of diverse electron acceptors display that
the ligands bias the specificity of both human and plant POR
rather than inhibiting their function. Single molecule Förster (or
Fluorescence detected) Resonance Energy Transfer (smFRET)
provides mechanistic insights showing that ligand binding biases
conformational sampling of plant POR, providing a link from
biased conformational sampling to biased redox partner specifi-
city. Lastly, we show that ligands alter CYP-mediated steroid
hormone metabolism in human cells and microsomes empha-
sizing the biological relevance and applicability of controlling
metabolic outcomes by targeting POR. Our data support a model
of biased metabolism, a mechanism akin to biased signaling of
GPCRs: POR conformational states are optimized to interact with
certain CYPs and are linked to distinct downstream metabolic
outcomes. Ligand-mediated control of POR conformational
sampling thus appears to inhibit the activation of a subset of
CYPs and/or enhance activation of others offering a new para-
digm of metabolic control.
Results
Binding of POR ligands induce biased specificity towards
electron acceptors. Using computational docking simulations on
POR crystal structures, we assessed the possible binding of small-
molecule ligands that are known to affect the function of specific
CYPs (Fig. 1A). Initial ligand selection was based on combination
of the annotated subset of chemicals and approved drug subset
from Drugbank following Lipinski Rule-of-Five descriptors and
principal component analysis (see Supplementary material and
Supplementary Fig. 1A). Based on docking simulations and
functional activity assays, three structurally diverse ligands with
promising effects on POR function were selected for detailed
studies (Fig. 1B). Tested molecules showing weaker or no effects
on POR function are displayed in Supplementary Fig. 1B. The
three promising candidates were; (a) rifampicin, an antibiotic that
induces expression and function of several CYPs22, (b) cyclo-
phosphamide, a chemotherapeutic prodrug which induces
expression of several CYPs23, and (c) dhurrin, a plant defense
compound which biosynthesis requires the coordinated assembly
and function of POR, two CYPs and a glucosyltransferase in
dynamic metabolons1,11.
Potential binding sites on POR were identified based on a
SiteMap analysis24 on human POR in a compact conformation
(PDB 3QE213) and using rat POR in an extended conformation
(PDB 3ES97). Rat POR shows 94% sequence identity with human
POR (see Supplementary Fig. 2 for sequence alignment) and was
chosen in the absence of a human POR extended conformation
and in preference of the available human-yeast chimeric structure
(PDB 3FJO25). The analysis on the two isoforms yielded five
binding sites on each structure (see Supplementary Fig. 3A and
Supplementary Table 1 for site scores, exposure and enclosure
parameters). The ligands were docked into these binding sites,
and all displayed a clear preference towards Site I on both
structures with estimated binding energies ranging from −5 to
−7 kcal/mol (see Supplementary Table 2). On human POR, Site I
extends throughout the interface between the FMN-, FAD- and
NADPH-binding domains comprising a relatively large volume.
Both cyclophosphamide and dhurrin docked into two subsites of
human POR Site I, called Ia and Ib, with almost equal binding
energies, while rifampicin only docked into Site Ia (Fig. 1B and
Supplementary Fig. 4). Site Ia forms a cavity partly comprised by
the FAD and NADPH cofactors with the docked ligands
extensively exposed to the surrounding solvent, while Site Ib lies
at the interface between the FMN- and FAD-binding domains
distant from the cofactors and further embedded into the protein
structure. All three ligands were predicted to interact via H-bonds
and π-π stacking to several amino acid residues on both POR
isoforms (see Supplementary Figs. 3 and 4 and Supplementary
Table 2). 1 microsecond molecular dynamics (MD) simulations
confirmed these interactions and revealed stable binding for all
three ligands upon an initial equilibration phase (see Supple-
mentary Fig. 5 for detailed interactions and Supplementary
Movies 1–4 displaying binding modes for each ligand). Tested
ligands were found to interact primarily with amino acids that are
conserved between human, rat and plant POR (see Supplemen-
tary Fig. 2 for sequence alignment), albeit each ligand interacted
in different ways with additional specific amino acids (see
Supplementary Fig. 5). Interestingly, all three ligands were found
to interact directly with either one or both of amino acid residues
G539 and R600 of human POR (see Supplementary Fig. 4 and
Supplementary Table 2). Mutations of the very same residues are
associated with POR deficiency. Patients with pathogenic
mutations G539R and R600W suffer from disorder of sexual
development due to low production of sex steroids indicating that
this site is important for POR specificity towards steroid-
metabolizing CYPs4,12.
Our in vitro studies showed these ligands to bind on POR and
regulate its function. Ligand binding on POR for all three ligands
was confirmed by intrinsic fluorescence quenching assays (see
Supplementary Methods and Supplementary Fig. 6). The
recorded quenching was in agreement with MD simulations
showing strong interaction of all three ligands with tryptophan
and tyrosines (W679, Y458, Y481) in both site Ia and Ib
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(Supplementary Fig. 5)26. To quantify the effect of ligand binding
on POR function we performed in vitro functional assays on
human POR proteoliposomes using cytochrome c (Cytc) as an
electron acceptor (Fig. 1C, D, see Supplementary Methods and
Supplementary Fig. 7 for spectral controls). All three ligands
displayed a strong effect on the capacity of POR to reduce Cytc.
Rifampicin caused an activity decrease to 14 ± 5% of control,
defined as POR activity without drug in otherwise identical
conditions. Dhurrin caused a decrease to 48 ± 9% of control,
while cyclophosphamide appeared to cause an increase to 119 ±
14% of control. All compounds were tested at 100 μM using 40
μM Cytc and 100 μM NADPH as substrates. The fact that the
bound ligands modulate activity supports that POR can be a
target for metabolic regulation and a modulator of therapeutic
activities. The observations that rifampicin and cyclophospha-
mide are known to interact with liver CYPs like CYP2B627 and
CYP3A428 furthermore shows that direct binding on POR should
be taken into consideration when screening for drug-CYP
interactions.
Given that point-mutations in human POR can lead to altered
specificity towards CYP isoforms4,19, we tested whether small-
molecule ligands can bias the specificity of human POR to reduce
diverse electron acceptors. Comparative in vitro activity assays
were carried out using commonly employed artificial electron
acceptors of POR; Cytc29,30, resazurin (RS)31 or 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)32
(Fig. 2A). Each of the assays relies on spectral changes of the
electron acceptor upon reduction by POR and thus directly
Fig. 1 Small molecules dock on human POR and regulate electron transfer in vitro. A POR is the omnipotent electron donor to all CYPs in the ER
membrane, activating metabolic cascades in both human and plants by transferring electrons to redox partners. Targeting POR with small-molecule ligands
may bias metabolic outcomes and regulate basic metabolism in humans or tune the formation of natural products in plants. B Molecular structures of
small-molecule ligands and their respective binding. Ligands (green) were docked on human POR with cofactors (yellow) in a compact conformation (PDB
3QE2) in Sites Ia and Ib determined from SiteMap analysis (see Supplementary Fig. 3A and Supplementary Table 1). Insets display the predicted binding
conformations of cyclophosphamide (a+ d), dhurrin (b+ e), and rifampicin (c). See Supplementary Figs. 3–5 for higher magnification and detailed
interactions and Supplementary Table 2 for binding energies. C In vitro activity of human POR proteoliposomes measured by the commonly used Cytc
assay29. D Ligands bias human POR capacity to reduce Cytc in proteoliposomes at 100 μM, acting either as agonist (cyclophosphamide) or inverse
agonizts (dhurrin and rifampicin). The bar plot represents the mean ± SD of independent replicates (n= 2–3; see Supplementary Table 3 for exact value of
n for each experimental condition). Overlapping data points appear shaded. Level of significance is determined by one-way ANOVA and Tukey’s HSD test
correcting for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Methods and Supplementary Table 3 for details). Source data
are provided as a Source Data file.
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reports on POR activity towards reducing the specific redox
partner (see Supplementary Methods for details). Being com-
parative these assays exclude artefacts that may originate from
potential FMN loss. Cyclophosphamide caused an increase in
POR capacity to reduce resazurin (115 ± 7% of control at 10 μM)
and appeared to cause an increase in POR capacity to reduce Cytc
(119 ± 14% of control at 100 μM) but had no significant effect in
neither the MTT when tested at 10 or 100 μM (Fig. 2B). This
supports that binding close to FAD and NADPH cofactors does
not reduce or eliminate activity by non-specifically hindering
POR motions and prohibiting electron transfer between FAD and
FMN. Dhurrin, which caused an activity decrease in the Cytc
assay (48 ± 9% of control), only showed very minor effects in the
MTT and RS assays (96 ± 3% and 82 ± 6% of control, respec-
tively), see also Supplementary Fig. 8 for dose-response curves of
dhurrin on hPOR in microsomes. The presence of rifampicin
caused a dramatic increase in POR capacity to reduce RS (312 ±
16% of control) and a smaller but significant increase in reduction
of MTT (122 ± 3% of control; see Fig. 2B) (see Supplementary
Table 3 for detailed data). This is striking as rifampicin decreased
POR capacity to reduce Cytc (14 ± 5% of control at 100 μM) and
highlights that small-molecule ligands can bias the specificity of
POR towards reducing diverse electron acceptors in a way similar
to biased agonism of GPCRs.
POR ligand binding and biased specificity pertain across
mammal and plant kingdoms. POR plays an omnipotent role as
an electron donor to microsomal CYPs in all eukaryotes and
serves as a key metabolic hub in plants as well as humans1. To test
whether the effect of small-molecule ligand binding to POR is an
omnipotent phenomenon underlying the regulation of POR in
organisms from different kingdoms, we performed binding assays
Fig. 2 Small-molecule ligands bias specificity of human POR to reduce diverse electron acceptors. A Human POR proteoliposome activity to reduce
diverse electron acceptors was assessed using 100 μM NADPH and 10 μM RS (left), 500 μM MTT (middle) or 40 μM Cytc (right) by monitoring changes
in absorbance (550 nm for Cytc, 610 nm for MTT) or fluorescence (582 nm for RS). Note the increased noise due to less sensitive UV–VIS readout for
Cytc. All activity traces depict the mean ± SD of at least three independent measurements. POR activity was extracted by fitting the linear region of the
traces. B Ligands affect the electron donating capacity of human POR differentially dependent on the electron acceptor indicating biased specificity.
Rifampicin reduces POR activity towards Cytc, has a small effect on MTT reduction and enhances POR activity to reduce the electron acceptor resazurin by
3-fold. Cyclophosphamide results in minute increased activity towards Cytc, while dhurrin reduces activity towards Cytc. The bar plot represents the mean
± SD of independent replicates normalized to DMSO controls with propagated error (n= 2–6; see Supplementary Methods and Supplementary Table 3 for
exact value of n for each experimental condition). Note, overlapping data points appear shaded. Data for Cytc from Fig. 1 are included for comparison. All
data are corrected for potential ligand photophysical effect (see Supplementary Fig. 7). Level of significance is determined by one-way ANOVA and Tukey’s
HSD test correcting for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Material for details). Source data are provided as a
Source Data file.
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based on intrinsic fluorescence quenching and dose-response
experiments on POR2b from the crop plant Sorghum bicolor
(SbPOR2b) in proteoliposomes (Fig. 3A, B, Supplementary Fig. 6
and Supplementary Table 3). Consistent with docking studies
showing all three ligands binding on POR, Rifampicin increased
SbPOR2b capacity to reduce Cytc while marginally reducing the
capacity in the RS assay (179 ± 35% and 85 ± 13% of control at
100 μM, respectively) with IC50 values of 9 ± 8 μM and 18 ± 9
μM, respectively (see Fig. 3B and Supplementary Fig. 9 discussing
an observed lag phase). Cyclophosphamide appeared to cause the
opposite effect resulting in an activity decrease in Cytc reduction
and increase in RS reduction (80 ± 14% and 127 ± 20% of control
at 500 μM, respectively) with IC50 values of 228 ± 208 μM and
159 ± 136 μM, respectively (Fig. 3B). Note the large standard
deviations due to low affinities. Michaelis–Menten kinetics of
SbPOR in the presence of the three ligands show ligand to pri-
marily affect Vmax supporting biased ligand binding is not com-
petitive (see Supplementary Fig. 11 and Supplementary Methods).
Careful inspection of the rifampicin and cyclophosphamide IC50
curves is reminiscent of biased agonism (Fig. 3B). Rifampicin
appears to operate as an inverse agonist inhibiting RS reduction
and agonist increasing Cytc reduction. Cyclophosphamide, on the
other hand, displays the opposite behavior and operates as an
agonist towards RS reduction and inverse agonist towards Cytc
reduction. Interestingly, human and plant isoforms respond dif-
ferently to the same ligand, in line with differential response of
GPCRs isoforms by the same ligand33,34. The fact that the spe-
cificity of both human and plant POR isoforms can be biased by
the tested ligands, albeit to a different extent probably due to a
low sequence identity of 38%, indicate that biased agonism may
not be an exclusive property of receptor-mediated signaling15 but
also a method to regulate the function of metabolic cascades
across kingdoms.
The natural product dhurrin caused increased SbPOR2b
activity towards both Cytc and RS (156 ± 17% and 236 ± 96% of
control at 100 μM, respectively) with IC50 values of 21 ± 12 μM
and 35 ± 13 μM, respectively (see Supplementary Table 3 for
detailed data and replicates). The observed effect is inverted at
concentrations above 100–500 μM dependent on the assay,
indicating a negative feedback loop type of mechanism down-
regulating dhurrin production in plants at high dhurrin
concentrations (see Supplementary Methods and Supplementary
Fig. 7 for control on dye photophysics). This may originate from
lower binding affinity of dhurrin to alternative binding sites (see
Supplementary Fig. 3 and Supplementary Table 2). The potential
feedback loop may by supported by the fact that dhurrin
accumulates at high (~100mM) concentrations in sorghum35
thus making activation of a feedback loop at these concentration
Fig. 3 Small-molecule ligands bias specificity of plant POR (SbPOR2b) to reduce diverse electron acceptors. A Effects of small-molecule ligands on
SbPOR2b activity in proteoliposomes using Cytc and RS as electron acceptors. B Dose-response curves of rifampicin, cyclophosphamide and dhurrin in the
Cytc and RS assays, respectively. Rifampicin acts as an agonist towards Cytc enhancing its reduction rate and inverse agonist towards RS reducing the
reduction rate. Cyclophosphamide displays the reverse effect acting as an inverse agonist towards Cytc reduction and agonist towards RS reduction.
Dhurrin acts as an agonist towards both Cytc and RS reduction at low micromolar concentrations. The fact that ligands display differential effects on
SbPOR2b activity to reduce the two electron acceptors indicates biased specificity of POR. IC50 values are extracted from the Hill equation. A, B The bar
plots and dose-response curves represent the mean ± SD of independent replicates normalized to controls with propagated error (n= 3–12; see
Supplementary Fig. 9 for raw data and Supplementary Table 3 for exact value of n for each experimental condition). All data are corrected for potential
ligand photophysical effect (see Supplementary Fig. 7). Note, overlapping data points appear shaded. Level of significance is determined by one-way
ANOVA and Tukey’s HSD test correcting for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Material for details). Source
data are provided as a Source Data file.
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levels a likely event. Deciphering whether dhurrin is a generic
regulator biasing POR-mediated CYP metabolism across all PORs
is an exciting possibility that requires additional experimental
verification. Ligands also have an effect on POR reconstituted in
detergent micelles (Supplementary Fig. 10 and Supplementary
Table 5), albeit the amplitude and precise effects are different as
compared to liposomes. Similar finetuning of the effects of
ligands by membrane and protein microenvironment was found
for hPOR in liposomes and microsomes (see also Supplementary
Fig. 8 for data on hPOR in microsomes). This is not surprising as
earlier studies on POR31,36 and additional membrane spanning or
membrane associated proteins37–39 have shown both protein
dynamics and function to be altered in detergents and to be
dependent on membrane properties40–44. POR protein and
membrane microenvironment may thus finetune the effect of
ligands and should be taken into consideration when analyzing
POR dynamics and function. The fact that each ligand introduces
diverse effects on POR capacity to reduce electron acceptors
indicates that POR operates as a central metabolic hub integrating
multiple layers of regulatory inputs (ligand conditions, subcellular
localization, membrane environment and mutations) to tune the
transferred electrons to CYPs and other redox partners,
consequently controlling metabolic cascades. This opens up the
possibility to use POR as a target for regulating natural product
biosynthesis in plants, basic metabolism in humans, and optimize
synthetic biology approaches for production of bioactive
metabolites1,11.
Direct observation of POR conformational sampling and its
remodeling by ligands. Biased specificity is well established for
receptors, and documented to operate via biased conformational
sampling15–17. POR is a highly dynamic protein oscillating between
compact and extended conformations to execute electron transfer to
CYPs. This has been verified by ensemble techniques including
electron paramagnetic resonance (EPR)10, nuclear magnetic reso-
nance (NMR)6,9, small-angle X-ray scattering (SAXS)6,10,45, small-
angle neutron scattering (SANS)5, fluorescence30, and stopped-flow
ultraviolet-visible (UV–VIS) spectroscopy46, providing insights into
POR conformational sampling recently confirmed by smFRET
burst analysis18,47. Mutations known to control POR specificity and
to cause metabolic disorders are often found in the hinge region of
POR that controls conformational dynamics4,12,13. We therefore
hypothesized that POR biased specificity might originate from
biased conformational sampling.
We used Total Internal Reflection Fluorescence (TIRF)
microscopy48–50 to record smFRET traces and directly observe
conformational sampling of SbPOR2b and its remodeling by
ligands. Data were recorded using the Alternating-Laser
Excitation (ALEX) methodology51,52 that we and others have
been using extensively47,48,53. POR was site-specifically labeled
with Cy3 and Cy5 fluorophores using a minimal cysteine full-
length SbPOR2b variant with two solvent accessible cysteines
(N181C/C536S/A552C) that we have recently used for smFRET
without impairing activity18. The dual-labeled SbPOR2b was
reconstituted in nanodiscs, which maintain the native structure
and minimize non-specific interactions with the microscope
surface18,31 (Fig. 4A and Supplementary Fig. 12A for raw
images). By monitoring FRET of hundreds of single POR
enzymes in parallel, we were able to quantify the conforma-
tional sampling of POR and its remodeling by the ligands
(Fig. 4A). Rapid and agnostic annotation and classification of
the single molecule FRET data was carried out using
DeepFRET54, our recently published methodology based on
machine learning (see Supplementary Methods for details on
data fitting, occupancy extraction and FRET to distance
calibration). A wide range of conformations with average FRET
distances varying from ~40 to ~90 Å were observed (see
Supplementary Fig. 12B for representative traces and Supple-
mentary Fig. 13 for calibration using ALEX). Inspection of
individual traces revealed relatively stable fluorescence and only
rare transitions between FRET states (Fig. 4A and Supplemen-
tary Fig. 12B). This is expected as POR dynamics related to
function takes place at the low millisecond time scale6,31,46.
Imaging with a temporal resolution of 200 ms thus results in
FRET states representing the equilibrium between one or more
protein conformations. Indeed, decreasing the temporal resolu-
tion from 200 ms to 1 s still results in multiple distinct FRET
states, however with a slightly higher fraction of traces showing
dynamic transitions (from 4–8% to 10–14%; see Supplementary
Fig. 13) due to longer observation times. Increasing temporal
resolution to timescales faster than 200 ms was not possible
without compromising signal-to-noise. Fluorescence cross
correlation studies yield Pearson coefficients centered around
zero for all conditions, indicating that transitions between
conformational states are masked due to dynamics faster than
the temporal resolution (200 ms), in agreement with our
simulations and similar readouts for GPCRs16 (Supplementary
Fig. 13). Thus, the observation of multiple discrete FRET states,
as well as a low fraction of transitions between them, originates
from long-lived protein states as previously observed39,55–57.
The FRET distribution of the native enzyme (n= 243) as well
as all data combined (n= 418) were best fit with a mixture of five
gaussians implying at least five underlying FRET states (see BIC
analysis in Supplementary Methods and Supplementary Fig. 13)
in agreement with earlier studies18. A five-state model was used to
quantify the abundance of FRET states (Fig. 4B, C). In the native
form, the inter-dye distances of the five FRET states were 76 Å,
64 Å, 57 Å, 48 Å and 44 Å (see Supplementary Fig. 13 and
Supplementary Methods for FRET to distance calibration). We
modeled the structure based on human POR in a compact
conformation (PDB 3QE213), rat POR in an intermediate
conformation (PDB 3ES97) and a human-yeast chimera in a
fully extended conformation (PDB 3FJO25) as no crystal structure
exists of SbPOR2b (see Fig. 4D and Supplementary Methods).
The expected inter-dye distances calculated from dye-linker
Monte Carlo simulations58 on the three homology models were
31 Å, 59 Å and 97 Å, respectively, in agreement with our earlier
burst analysis studies18 (see Supplementary Methods), further
supporting each FRET state reflects an equilibrium between
multiple conformations. We call these equilibrium states S1–S5,
respectively. The occupancies of the five states were 17%, 25%,
16%, 27% and 14%, respectively, implying that states S2 and S4
are the most dominant.
To evaluate the effect of ligands on POR conformational
sampling, we measured smFRET on POR exposed to ligand
concentrations above IC50s. Ligand binding did not significantly
affect the center of the FRET states (gaussian means), but rather
their occupancies, indicating a changed equilibrium between
long-lived protein equilibrium states (Fig. 4B, C). Rifampicin at
100μM shifted the equilibrium towards S1 at the expense of S4
and S5. S1 practically doubles its occupancy from 17% to 33%,
while S4 decreases from 27% to 19%, but also slightly shifts its
center indicating S5 slightly decreases from 14% to 11%.
Cyclophosphamide was tested at 200 μM due to higher IC50
values (see Fig. 3) and was found to shift the equilibrium towards
S3 (22% from 16%) and S4 (34% from 27%) at the expense of S5
and S1 (4% from 14% and 15% from 17%, respectively). Dhurrin
was tested at 1 mM that appear to result in opposite responses for
resazurin and Cytc reduction and was found to induce a small
shift in the equilibrium between S3 and S4 (S3 increases from
16% to 22% while S4 decreases from 27% to 19%). Rifampicin
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and cyclophosphamide seem to have opposed effects on
conformational sampling. Rifampicin shifts the equilibrium
towards extended states whereas cyclophosphamide shifts the
equilibrium towards intermediate and compact states (albeit not
fully compact S5). Interestingly, rifampicin and cyclophospha-
mide also have opposing effects on SbPOR2b specificity when
monitored in vitro. Rifampicin operates as an agonist on Cytc
reduction and inverse agonist on RS reduction, while the effect of
cyclophosphamide is reversed. These data thus support a
correlation between conformational sampling and substrate
specificity. Ligand binding on POR appears to bias conforma-
tional sampling stabilizing certain equilibrium states at the
expense of others, consequently promoting the inhibition or
activation of a subset of electron acceptors.
POR ligands bias steroid hormone metabolism in human cells
and microsomes. We tested the efficiency of the three ligands to
elicit a physiological response on steroidogenic CYP activities in
cells (Fig. 5A, see Supplementary Methods, Supplementary Fig. 14
and Supplementary Table 4 for all data and number of biological
replicates). The 3 tested ligands are not known to interact directly
with CYP17, CYP19 or CYP21, albeit rifampicin and cyclopho-
sphamide are known to interact with liver CYPs like CYP2B627
and CYP3A428. Using a human adrenocortical cell line (NCI-
H295R) we tested the effect of ligands on CYP17A1 and
CYP21A259,60 activities at 10 and 100 μM concentrations
(Fig. 5A). Using radiolabeled substrates, we were able to quantify
the steroid hormone production of CYP17A1 and CYP21A2 and
its remodeling by POR ligands (see Supplementary Methods for
Fig. 4 Direct observation of POR biased conformational sampling by small-molecule ligands using smFRET. A Illustration of smFRET assay using TIRF
microscopy. Top; SbPOR2b is site-specifically labeled with Cy3/Cy5 fluorophores, reconstituted in lipid nanodiscs and tethered on a passivated microscope
surface. Bottom; representative smFRET traces displaying FRET states and dynamic transitions between them (see Supplementary Fig. 12 for more
examples). Top row: Donor (green) and acceptor (red) intensities over time (s). Middle row: acceptor only intensity (red), bottom row: EFRET values
(orange) calculated with calibration factors, and idealized FRET value determined from HMM fitting (blue). B Distribution of FRET efficiencies in the
absence and presence of ligands. Distributions are optimally fit with 5 states for all conditions as determined from BIC (see Supplementary Methods and
Supplementary Fig. 13) with average distances ranging from ~40 to ~80 Å. Rifampicin, cyclophosphamide and dhurrin alter the occupancies of each of the
five FRET states indicating biased conformational sampling. Colored bars on top of histograms represent occupancies of each state. N denotes of the
number of single molecules at each experimental condition. C FRET efficiencies and converted inter-dye distances obtained from five-state gaussian
mixture models. Each FRET state may reflect an equilibrium between multiple conformations. D Homology modeling of SbPOR2b from crystal structures of
POR isoforms in a compact, intermediate conformation and a human-yeast chimera in a fully extended conformation (PDBs: 3QE2, 3ES9 and 3FJO
respectively) with Monte Carlo simulated inter-dye distances (bold) and Cα-Cα distances (brackets). Source data are provided as a Source Data file.
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details). Control experiments with the known CYP17A1 inhibitor
abiraterone at saturating concentration of 10 μM61 show specific
inhibition of the two CYPs (Fig. 5B and Supplementary Fig. 14).
Rifampicin caused no significant effect on CYP17A1 activity, but
reduced CYP21A2 activity at 100 μM (73 ± 4% of control; see
Fig. 5A and Supplementary Fig. 14). The cells capacity to reduce
MTT increased significantly (116 ± 3% of control at 100 μM).
Because MTT assay is not reliant on CYPs function, these data
further support that POR docking can facilitate biased CYP
activation in cellular environment. The fact that CYP21A2
activity was reduced indicates that the observed increase in MTT
reduction is not attributed to increased overall reductase
expression22, but rather remodeling of activity. Cyclopho-
sphamide significantly enhanced CYP17A1 lyase activity and had
less pronounced effect on hydroxylase activity at 100 μM (132 ±
8% and 111 ± 1% of control, respectively), while having a small
yet statistically insignificant effect on CYP21A2 activity (113 ±
11% of control) based on t test analysis (See Supplementary
Fig. 5 Biased metabolism: small-molecule ligands bias steroidogenic CYP-activities in human cells and microsomes. A A human adrenocortical cell line
(NCI-H295R) was used to assess the effect of small-molecule ligands on steroidogenic CYP17A1 and CYP21A2 hydroxylase activity, and CYP17A1 lyase
activity, using radiolabeled substrates (see Supplementary Methods and Supplementary Table 4). Cell viability was assessed based on MTT reduction.
Rifampicin shows a small inhibiting effect towards CYP21A2. The cells display increased MTT reduction indicating increased reductase activity. No
significant effects on CYP17A1 activities are observed. Cyclophosphamide causes a significance increase in CYP17A1 lyase and less significant towards 17-
OHase and 21A2 activities, while MTT reduction decreases slightly. Dhurrin causes inhibition of both CYP17A1 and CYP21A2 activities. B Abiraterone was
used as a control inhibitor of CYP17A1 and CYP21A2 in H295R cells. C The effect of ligands on CYP19A1 activity was assessed on microsomes from a
human choriocarcinoma cell line (JEG3). Rifampicin shows a concentration dependent inhibitory effect on CYP19A1 activity (32 ± 11% of control).
Cyclophosphamide and dhurrin display no significant effect. A, C Error bars represent mean ± SD of 3–4 biological replicates normalized to DMSO controls
with propagated error. See Supplementary Fig. 14 for raw data and Supplementary Table 4 for exact value of n for each experimental condition. Note,
overlapping data points appear shaded. Level of significance is determined by one-way ANOVA and Tukey’s HSD test correcting for multiple comparisons
(*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Methods for details). Source data are provided as a Source Data file.
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Methods). Dhurrin caused a decrease in CYP21A2 hydroxylase
and CYP17A1 lyase activities (44 ± 11% and 80 ± 7% of control at
100 μM, respectively). Interestingly, CYP17A1 hydroxylase
activity was not significantly affected by dhurrin (91 ± 12% of
control). Specific inhibition of CYP17A1 lyase activity and not
hydroxylase activity, that is relevant in the treatment of prostate
cancer and polycystic ovary syndrome59, may thus be achieved by
targeting POR as an alternative to targeting CYP17A1 directly.
One may argue that the tested ligands may dock on additional
proteins, CYPs or receptors, and induce convoluted physiological
responses additional to what is reported here22,23. Our combined
docking simulations, functional data, and smFRET structural
data, illustrate that the ligands also dock on POR and affect its
specificity towards reducing diverse electron acceptors.
To test the effect of ligands on CYP19A1 aromatase activity, we
used microsomes extracted from a human choriocarcinoma cell
line (JEG3)60. Radiolabeled substrate was used to quantify
CYP19A1 activity and its remodeling by POR ligands (see
Supplementary Methods for details). Cyclophosphamide and
dhurrin did not show any significant effects at 10 nor 100 μM,
while rifampicin significantly reduces CYP19A1 activity at
100 μM (32 ± 11% of control) (Fig. 5C and Supplementary
Table 4). The microsome results further confirm that the
observed effects are caused by biased activities and not via
altered protein expression levels. The fact that the small-molecule
ligands affect activities of steroidogenic CYPs in cells and
microsomes is a key finding confirming the biological relevance
of POR controlling metabolic cascades. The data confirm our MD
simulations, in vitro assays and structural dynamics studies by
smFRET, and support that biased conformational sampling of
POR induced by ligands results in altered specificity towards
CYPs. Ligand binding on POR thus appears to inhibit the
activation of a subset of CYPs and/or enhance activation of
others. We assign the term biased metabolism to this phenom-
enon since the mechanism is akin to biased signaling of receptors.
We propose that biased metabolism represents an extra layer of
regulatory control guiding metabolic pathways in complex
cellular environments.
Discussion
Protein conformational sampling, the dynamic exploration of
conformational space, governs all major aspects of protein
behavior from folding to function. Protein conformational states
are often found to elicit distinct functional outcomes55,62,63.
GPCRs are the prime example of this phenomenon, acting as key
signaling hubs with several conformational states linked to dis-
tinct downstream cellular processes15–17. The combined studies
presented here substantiates earlier studies on POR18 and point to
POR as being at the center of key metabolic hubs regulating the
activation of CYPs and therefore metabolic pathways1,3,4. While
our data do not distinguish between the swinging and rotating
motion models of POR8 they provide a correlation between the
existence of POR equilibrium conformational states with distinct
phenotypic metabolic outcomes.
Key advancement in our understanding of protein-ligand
interactions has opened the possibility for the development of
drugs that act on the same protein and selectively stabilize protein
states, consequently controlling different cellular outcomes, a
phenomenon described as biased agonism15. Biased agonism is
well studied, brought into practice and explicitly exploited to
underpin the function of signaling hubs like GPCRs. In our
current study the combined data on the three chosen small
molecules tested as ligands for POR serve as proof of concept of
the mechanism of biased metabolism, a mechanism similar to
biased agonism of GPCRs, but for metabolic hubs like POR.
While the working concentrations (10–100 μM) are rather high,
they support the electron transfer of POR to respond to different
ligands in a pluripotent way; ligand binding on POR redistributes
the conformational equilibrium, consequently altering interaction
with CYPs and downstream metabolism (see Fig. 6). Future
studies may fully confirm each equilibrium conformational state
to be directly linked to distinct downstream metabolic outcome.
Biased metabolism would operate in parallel with existing and
well-studied regulatory cues controlling CYP-mediated metabo-
lism and it appears to be finetuned by variations in protein and
membrane microenvironment. Interestingly, even small varia-
tions in the conformational sampling equilibrium induced by
ligand binding suffices for large variations in metabolic outcomes.
Thus, minute variations on ligand protein interactions, originat-
ing either by structurally diverse ligands or by different POR
isoforms, may be manifested as varied metabolic responses.
Although these ligands may also interact with additional
proteins22,23 our combined in vitro, binding and functional
assays, single molecule and in vivo data clearly support that their
binding on POR can facilitate biased metabolism. They also
highlight the significance of testing small-molecule drugs and
metabolites for binding on POR during early drug discovery and
high-throughput CYP screening assays2. We propose that biased
metabolism represents an extra, hitherto unrecognized, layer of
Fig. 6 Cartoon representation of the concept of biased metabolism a mechanism akin to biased signaling of GPCRs but for metabolic hubs. Ligand
binding on POR appears to remodel its energy landscape, alter its conformational sampling consequently biasing downstream CYP activation by inhibiting
the activation of a subset of CYPs and/or enhancing the activation of others. Targeting POR may act as a hitherto unknown paradigm for metabolic control
in human and plants. Complete understanding of biased metabolism may offer the in silico design of pathways specific pharmaceutics or personalized food
suppressing undesired, disease related, metabolic pathways.
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regulation capable of controlling metabolic pathways in complex
cellular environments. Targeting POR may serve as a way of
controlling POR-CYP interactions and regulate CYP-mediated
metabolic pathways. This is further compounded by the direct
interaction of the tested ligands with amino acids where mutation
is associated with POR deficiency and specifically disorder of
sexual development and production of sex steroids. Our findings
thus pave the way for the in silico design of pathway-specific
biased ligands.
The fact that both plant and human POR isoforms, with a
sequence identity of 38%, present responses to ligand binding
may indicate the presence of evolutionary conserved hotspots
serving to tune the specificity of POR. Indeed, sequence
alignment between human, plant and rat POR reveals structu-
rally conserved amino acids, some of which are shown by our
MD simulation to interact strongly with the tested ligands (see
Supplementary Figs. 2 and 5), supporting the existence of
ligand binding hotspots. Additional, across kingdoms, bioin-
formatics analyses are required to investigate whether hotspots
for ligand binding pertain across the entire spectrum of POR
isoforms. Interestingly, the plant defense compound dhurrin
binds on both human and plant POR and affects its dynamics,
function and metabolic response in cells. Since dhurrin is a
natural compound produced by a POR-CYP metabolon, these
findings open up the exciting possibility of controlling bio-
synthetic metabolism via feedback loop mechanisms in the
production of high-value natural products. Also, our results
provide a mechanistic clue explaining why many substances in
food, beverages and dietary supplements may affect basic
metabolism and induce food-drug interactions64,65 as dhurrin
is ingested as part of foods66,67. It is therefore worth investi-
gating whether additional plant or human metabolic inter-
mediates, only present at specific developmental stages or in
specific tissues, may bind to POR and bias POR-mediated
metabolism.
The combined insight here may pave the way for the design of
personalized, plant-based food targeting POR to alleviate meta-
bolic disorder or dietary supplements composed of natural pro-
ducts to suppress specific undesired metabolic pathways
associated with disease. Harnessing the structural basis of con-
formational sampling in biased metabolism may also offer the
design of metabolic pathway-specific ligands that antagonize
detrimental metabolic pathways while stimulating beneficial
downstream processes, with the possibility to control basic
metabolism and alleviate metabolic disorder. This could have
direct implications in biomedicine for enhancing therapeutically
relevant metabolic pathways. Quantitative, single molecule
structural and functional studies will be crucial in this endeavor of
deciphering and controlling POR-mediated metabolism via
biased ligands.
Methods
Chemicals and materials. All chemicals were of analytical grade and purchased
from Sigma-Aldrich (Merck) unless otherwise stated. Phospholipids, 2-dilauroyl-
sn-glycero-3-phosphocholine (DLPC) and 1,2-dilauroyl-sn-glycero-3-phosphogly-
cerol (DLPG), and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(cap
biotinyl) (Biotinyl Cap PE) were purchased from Avanti Polar Lipids. Dhurrin was
chemically synthesized in-house1,11. Bio-Beads SM-2 were purchased from Bio-
Rad. 2’5’-ADP Sepharose size exclusion chromatography (SEC) column Superdex
200 HR 10/30 for high-resolution preparative separation were from GE Healthcare
Life Sciences. Bottomless 6 channel (30 μL) sticky slides were purchased from ibidi
GmbH. PLL(20 kDa) grafted with PEG(2 kDa) (PLL-PEG) and PLL(20 kDa)
grafted with PEG-Biotin (3.4 kDa) (PLL-PEG-biotin) was purchased from SuSoS
AG. NeutrAvidin protein was purchased from Thermo Fisher Scientific. Expression
vectors were purchased from GenScript Biotech.
Radiolabeled substrates [3H]-pregnenolone, [3H]-androstenedione, [3H]-
progesterone, [14C]-progesterone were obtained from PerkinElmer and American
Radiolabeled Chemicals Inc. Silica gel-coated aluminum backed TLC plates were
purchased from Macherey-Nagel. The tritium screens used for the autoradiography
were purchased from Fujifilm. Trilostane was extracted in absolute ethanol (EtOH)
from tablets commercially available as Modrenal® (Bioenvision, NY, USA).
CYP17A1 was obtained from Cypex Limited. Human adrenal carcinoma cell line
(NCI-H295R) and human placental JEG3 cell line was purchased from American
Type Culture Collection (ATCC: CRL-2128 and HTB-36TM, respectively).
Selection of chemical compounds for initial studies. We used the Chemical
Entities of Biological Interest ChEBI (v. 194) and downloaded the annotated subset
of chemicals on 49.794 compounds as well as the approved drug subset on 2.355
compounds from Drugbank (v. 15.2). Only compounds containing C,H,N,O,P,S,F,
Cl,Br,I were included. After Lipinski Rule-of-Five descriptors were calculated and
compounds with a molecular weight above 1.000 removed, the datasets contained
37.708 and 2.035 compounds, respectively. The two dataset were combined and a
Principal Component (PC) analysis performed based on the four Lipinski Rule-of-
Five descriptors, which were normalized prior to the PC analysis (see Supple-
mentary Fig. 1). Preparation of the datasets, calculation of the Lipinski Rule-of-Five
descriptors and the PC analysis were all performed via a KNIME workflow. The
8 selected compounds were selected based on the PC analysis as structurally diverse
and based on experimental and/or clinical data that could be assimilated with
aberrant CYP function. Dhurrin was chosen as a representative of the family of
bioactive plant natural products termed cyanogenic glycosides that are present in
multiple components of the daily diet of humans. More than 3000 plant species
have been shown to contain Cyanogenic glycosides. The presence of cyanogenic
glycosides are five-times as common in domesticated crop species compared with
plants found in natural ecosystems66 and as such it is important to include a
representative of the class from an evolutionary perspective.
Protein expression and purification. Full-length human wild-type POR (NCBI
reference sequence: NP_000932.3 [https://www.ncbi.nlm.nih.gov/protein/
NP_000932.3/]) subcloned into pET22b vectors (GenScript Biotech) was expressed
in E. coli BL21(DE3)3. The cDNAs for POR in pET22b vector were transformed
into the Escherichia coli BL21(DE3), single colonies were selected for growth on
ampicillin and grown in terrific broth (pH 7.4) supplemented with 40 mM FeCl3, 4
mM ZnCl2, 2 mM CoCl2, 2 mM Na2MoO4, 2 mM CaCl2, 2 mM CuCl2, 2 mM
H3BO3, 0.5 mg/ml riboflavin, 100 µg/ml carbenicillin at 37 °C to an optical density
(OD) 600 nm of 0.6 and temperature was reduced to 25 °C for 16 h. The bacterial
cells were collected by centrifugation, washed with PBS and suspended in 100 mM
Tris–acetate (pH 7.6), 0.5 M sucrose, and 1 mM EDTA and treated with lysozyme
(0.5 mg/ml) and EDTA (0.1 mM [pH 8.0]) at 4 °C for 1 h with slow stirring to
generate spheroplasts. The spheroplasts were pelleted by centrifugation at 5000 × g
for 15 min; and suspended in 100 mM potassium phosphate (pH 7.6), 6 mM
MgOAc, 0.1 mM DTT, 20% (v/v) glycerol, 0.2 mM PMSF, and 0.1 mM DNase I;
and disrupted by sonication. A clear lysate devoid of cellular debris was obtained by
centrifugation at 12,000 × g for 10 min, and then the membranes were collected by
centrifugation at 100,000 × g for 60 min at 4 °C. Membranes were suspended in 50
mM Potassium phosphate buffer (pH 7.8) and 20% (v/v) glycerol and stored at
−70 °C. Protein concentration was measured by RC-DC protein assay (Protein
Assay Dye Reagent, Bio-Rad, Hercules, CA). The bacterial membranes were used
directly for protein reconstitution in liposomes without further purification. We
note, that E. coli does not express any membrane-bound reductases nor CYPs
which would infer with our POR activity assays.
Full-length Sorghum bicolor POR2b (SbPOR2b; NCBI reference sequence:
XP_002444097.1 [https://www.ncbi.nlm.nih.gov/protein/XP_002444097.1]),
subcloned into pET52b vectors (GenScript Biotech) was expressed in E. coli
NiCo21 (DE3) cells (New England Biolabs). A 100 mL starter culture of terrific
broth (TB) supplemented with 50 μg/ml ampicillin was grown overnight at 37 °C,
220 RPM. The starter culture was diluted into 1 L of TB supplemented with
ampicillin in a wide bottom flask and incubated at 37 °C. Expression was induced
at OD600nm= 0.6 by addition of IPTG to a final concentration of 1 mM.
(-)-riboflavin at a final concentration of 1 μg/ml was also supplemented. Cells were
harvested after expression for 6 h at 25 °C. SbPOR2b mutant N181C/C536S/A552C
in pET52b was expressed in E. coli HI-ControlTM BL21DE3 strain (Lucigen) in
2*400 mL TB cultures in wide bottom flasks. 1 μg/mL FMN and 1 μg/mL FAD
were supplemented at the beginning of expression. Cells were harvested after 18 h
expression at 20 °C by centrifugation (5000 × g, 15 min). The cell pellet was re-
suspended in buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl) with 1 tablet
cOmpleteTM protease inhibitor cocktail (Roche) per 200 mL buffer. Cells were
lysed using a cell disrupter (Constant Systems Ltd) using a process pressure of 31
kPSI. Cell debris was sedimented by centrifugation (15,000 × g, 20 min) and
membranes were pelleted from the supernatant by subsequent ultracentrifugation
(200,000 × g, 1 h). The membrane pellet was homogenized in buffer (50 mM Tris-
HCl pH 7.5, 100 mM NaCl, 50 mM cholate) in a Potter-Elvehjem homogenizer.
100 μM FMN and FAD were also added to the solution to ensure excess cofactors.
The enzymes were purified from the membrane solution using 2′5′-ADP Sepharose
affinity chromatography and anion exchange chromatography according to
protocols adapted from previous publications18,31. In brief, the membrane solution
was applied to a 2’5’-ADP sepharose column equilibrated with 50 mM Tris-HCl
pH 7.5, 100 mM NaCl, 20 mM cholate. After washing, bound POR was eluted with
5 mM NADP+ in buffer. Fractions containing POR were subsequently pooled and
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applied to a Q-sepharose column. POR was eluted by increasing the salt
concentration to 400 mM.
Protein reconstitution in liposomes. Liposomes were prepared using a DLPC/
DLPG lipid mixture (3:1 ratio) dissolved in DMSO and placed in vacuum for ~4 h
to obtain dry lipid films. While kept on ice, lipid films were rehydrated with either
purified protein or bacterial membrane extract in a solution containing 50 mM
cholate to obtain final lipid:protein ratios of ~200 and protein concentrations of
2–20 μM. After 1 h of incubation on a shaking platform at 5 °C, biobeads (Bio-
Beads SM-2) were added to the mixture to extract detergent molecules. Upon
additional 2 h of incubation, samples were centrifuged briefly to remove biobeads
followed by centrifugation at 4000 × g and 5 °C for 10 min. Supernatant was col-
lected and transferred to eppendorf tubes. All samples were flash frozen and stored
at −80°C until further use.
Intrinsic fluorescence quenching assay. The interactions between human and
plant POR and the three ligands used here (dhurrin, cyclophosphamide and
rifampicin) were determined using intrinsic fluorescence quenching of aromatic
residues. Plant SbPOR2b in detergent (4.6 μM) was prepared in 50 mM Tris-HCl
(pH 7.5) containing 20 mM cholate and 100 mM NaCl, while hPOR in microsomes
was prepared in PBS buffer (pH 7.2) containing 10% glycerol. The fluorescence
quenching was measured on a fluorescence spectrometer (SpectraMax M2e,
Molecular Devices, CA USA) at room temperature. The samples were excited at
295 nm and emission was detected between 300 and 500 nm. Tryptophan fluor-
escence spectra were collected before and after addition of 100 μM of each of the
ligands. All data are corrected for negligible ligand fluorescence changes under the
same experimental conditions. Note that intrinsic fluorescence quenching provides
limited information about which tryptophan or even tyrosine is quenched, and
thus whether ligands dock on site Ia or/and site Ib. The observed significant
quenching fully supports that all three ligands dock on POR.
In vitro POR activity assays. The activity of full-length POR reconstituted in
either detergent micelles (20 mM cholate) or liposomes (DLPC/DLPG, 3:1 ratio) in
50 mM Tris-HCl buffer (pH 7.5) containing 100 mM NaCl was assessed spectro-
photometrically at 10–100 nM concentrations as described elsewhere29–32. Using
Cytc, MTT or RS as electron acceptors the change in absorbance (550 nm for Cytc
and 610 nm for MTT) or emission (570 nm excitation, 585 nm emission for RS)
was monitored as a function of time. Cytc and RS concentrations were both close to
KM of the given electron acceptor, while MTT and NADPH were in excess
amounts. Concentrations were 40 μM Cytc, 10 μM RS, 500 μM MTT and 100 μM
NADPH unless otherwise stated. POR activity was extracted from the slope of the
linear region of each trace. Michaelis–Menten kinetics and IC50 curves were
performed under identical conditions using relevant substrate and ligand con-
centrations. All measurements were repeated at least three times and subsequently
normalized to DMSO control measurements. All data were background corrected
and controls without POR showed negligible activity. Fluorescence intensities of
resorufin in the presence of rifampicin were corrected according to a linear cali-
bration curve (see Supplementary Fig. 7).
hPOR dose-response activity assays in microsomes. In a typical experiment
hPOR microsomes (100–500 ng/well) extracted from bacterial membrane was
allowed to react with 40 μM Cytc, 10 μM RS or 500 μMMTT in 100 mM phosphate
buffer (pH 7.2) in the presence of 100 μM NADPH and increasing concentration of
ligands (dhurrin, cyclophosphamide and rifampicin). All data were recorded with a
Spectramax M2e spectrophotometer (Molecular Devices, Sunnyvale, CA, USA) by
measuring the change in absorbance over time (550 nm for Cytc and 610 nm for
MTT) or emission (570 nm excitation, 585 nm emission for RS). Reactions were
started by addition of NADPH at 100 μM. See Supplementary Fig. 8 for data.
Cell lines and culture media. Cells were cultured according to established
protocols59,60. Human placental JEG3 cells were cultured in minimal essential
medium (MEM) with Earle’s salts (Thermo Fisher Scientific) supplemented with
10% fetal bovine serum, 1% L-glutamine (200 mM GIBCO), 1% penicillin (100 U/
ml; GIBCO), and streptomycin (100 μg/mL; Thermo Fisher Scientific). Human
adrenocortical NCI-H295R (NCI-H295R) cells were grown in DMEM/Ham’s F-12
medium containing L-glutamine and 15 mM HEPES (Thermo Fisher Scientific)
supplemented with 5% NU-I serum (Becton Dickinson), 0.1% insulin, transferrin,
selenium (100 U/mL; Thermo Fisher Scientific), 1% penicillin (100 U/mL; Thermo
Fisher Scientific), and streptomycin (100 μg/mL; GIBCO) and passage numbers
during the experiments remained below 30.
Preparation of microsomes and CYP19A1 activity assay using JEG3 cells.
Microsomes were prepared from JEG3 cells based on a protocol adapted from
previous work60. JEG3 cells were collected near confluency and washed with cold
PBS. The cell suspension was then centrifuged at 1500 × g for 5 min to pellet the
cells. The cell pellet was suspended in 100 mM Na3PO4 (pH 7.4) containing
150 mM KCl, and the cells were lysed by sonication. Unbroken cells and mito-
chondria were pelleted by centrifugation at 14,000 × g for 15 min at 4 °C.
Microsomes containing endoplasmic reticulum were collected by ultracentrifuga-
tion at 100,000 × g for 90 min at 4 °C and resuspended in 50 mM K3PO4 (pH 7.4)
containing 20% glycerol.
CYP19A1 activity was measured by the release of tritiated water from
radiolabeled substrates during aromatization60. First, 40 μg microsomes extracted
from JEG3 cells were incubated with 50 nM [1β-3H(N)]-androstenedione (~20,000
cpm/reaction) in buffer (100 mM NaCl, 100 mM potassium-phosphate, pH 7.4) for
5 min at 37 °C on a shaking platform. The reaction was initiated by adding 1 mM
NADPH. After 1 h of incubation at 37 °C, the reaction was stopped by adding a
mixture of 5% charcoal and 0.5% dextran. Samples were vortexed for 40 s and
centrifuged at 14,000 × g for 5 min. Supernatant was collected and diluted in
scintillation liquid (Rotiszint Universal Cocktail; Carl Roth GmbH) before
counting [3H]-radioactivity. All measurements were repeated at least three times
and subsequently normalized to controls.
CYP17A1 and CYP21A2 activity assay in H295R cell line. Steroidogenic
CYP17A1 and CYP21A2 activities in H295R cells were quantified based on radi-
olabeled substrate assays59,60. In brief, cells were plated in six-well plates and
treated with small-molecule ligands dissolved in 0.1% DMSO and normal growth
medium for 24 h, or for 4 h for rifampicin, to ensure protein expression levels are
not affected22. After incubation, 1 μM trilostane (a specific blocker of HSD3B) was
added to the medium for 90 min followed by addition of 1 µM radiolabeled sub-
strate ([3H]-17α-OH-progesterone or [3H]-pregnenolone; ~50,000 cpm). After 1 h
of reaction, steroids were extracted from cell supernatants and separated by thin
layer chromatography (TLC) on silicagel (SIL G/UV254) TLC plates (Macherey-
Nagel, Oensingen, Switzerland). The steroids were visualized on a Fuji FLA-7000
PhosphorImager (Fujifilm, Dielsdorf, Switzerland) and quantified using Multi
Gauge software (Fujifilm, Dielsdorf, Switzerland).
Steroid conversion was assessed as a percentage of incorporated radioactivity in
relation to total radioactivity measured for the whole sample. The conversion of
17α-OH-progesterone to 11-deoxycorticosterone was used as a measure for
CYP21A2 hydroxylase activity. The conversion of pregnenolone to 17α-OH-
pregnenolone and dehydroepiandrostenedione (DHEA) was used as a measure for
CYP17A1 hydroxylase activity, while the specific conversion of 17α-OH-
pregnenolone to DHEA was used as a measure for 17,20-lyase activity. All
measurements were repeated at least three times and subsequently normalized to
controls.
MTT cell viability assay. MTT reduction was used to evaluate cell viability and
simultaneously quantify reductase expression/activity of cells upon drug incubation
as described elsewhere60. In brief, 100 μL of cell solution containing ~3 × 104 cells
were placed in a 96-well plate at a concentration of upon 24-h incubation with
drugs. MTT was added in each well to a final concentration of 0.8 mg/mL.
Absorbance was measured at 610 nm on a plate reader to quantify reduction of
MTT. All measurements were done in triplicates and normalized to DMSO
controls.
Homology modeling and Monte Carlo simulation of dye-dye distances. Since
no 3D structure of SbPOR2b is available, the structure was modeled using SWISS
MODEL automated online server68 based on human, yeast and rat POR
isoforms18. The compact conformation of SbPOR2b was modeled based on human
POR (PDB 3QE213, chain A) while the intermediate and fully extended con-
formations were based on rat POR (PDB 3ES97, chain A) and a human-yeast
chimera (PDB 3FJO25), respectively. The isoforms share 38%, 40% and 36%
sequence identity to SbPOR2b, respectively.
To convert the modeled Cα-Cα distances between residues N181 and A552 to
expected dye-dye distances as measured by smFRET we used a toolkit developed by
Kalinin et al.58 based on Monte-Carlo simulations. The toolkit employs a geometric
accessible volume (AV) algorithm to predict the spatial distribution of donor and
acceptor dyes. Using an approximated linker length of 14.0 Å, linker width of 4.5 Å
and dye radius of 3.5 Å, the simulated dye-dye distances and modeled Cα-Cα
distances differ by 3.7–8.9 Å depending on protein conformation (see main Fig. 4,
panel D). The 14.0 Å long linker length ensures free rotation of the dyes, which is
essential for distance calibration.
Computational docking simulations on POR structures. The small molecules
were constructed in Maestro (v. 9.8, Schrodinger 2018-3 release, Schrödinger, LLC,
New York, NY, 2014) and prepared for docking in the LigPrep module69. Both
neutral and charged forms were generated and used as input structures for the
docking. The rifampicin structure was taken from a structure of rifampicin
monooxygenase complexed with rifampicin (PDB 5KOX70). Prior to docking,
rifampicin was subjected to the LigPrep module, which produced three different
conformations. After a short energy minimization these structures were used as
input structures for the docking.
Identification of potential binding sites was carried out using the SiteMap
software (v. 2.6, Schrödinger, LLC)24. All ligands were docked on the human POR
crystal structure (PDB code 3QE213, A-chain) as well as the rat POR crystal
structure (PDB code 3ES97, A-chain) representing the compact and extended POR
conformations, respectively, using Glide (v. 5.8, Schrödinger, LLC) with default
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settings (van der Waals scaling factor and partial charge cut-off at 0.80 and 0.15,
respectively; standard precision and flexible ligand sampling; no constraints)71,72.
All docking results are displayed in Supplementary Table 2.
MD simulation to evaluate the stability of top scoring docking conformations.
The stability of top scoring docking conformations was evaluated to be stable by
short MD simulations (embedded in water box, 10 ns) in Desmond (v. 4.3,
Schrödinger, LLC)73. The Desmond system builder was used to create an orthor-
hombic box with the protein-ligand complex embedded in an SPC water model
with a buffer size of at least 10 Å from the protein to the box boundary. The final
systems contained close to 72,000 atoms with ~9600 atoms from the protein, 200
atoms from cofactors and ligand, 62,300 atoms from water molecules and nearly
30 sodium ions to neutralize the systems.
Extended 1000 ns MD simulations were performed with the Desmond program
using the OPLS-2005 force field. Prior to the production simulations, the systems
were subjected to the Desmond standard stepwise equilibration procedure
comprising a restrained energy minimization of the solute, a 12 ps simulation at 10
K on an NVT ensemble, a 12 ps simulation at 10 K on an NPT ensemble, and a 12
ps simulation at room temperature on an NPT ensemble. Finally, the systems were
equilibrated without constraints for 24 ps at room temperature on an NPT
ensemble. After equilibration the systems were simulated for 1000 ns at 300 K and
1000 frames were collected and analyzed. Key parameters, Cα RMSD values and
protein-ligand contacts, for the MD simulations are collected in Supplementary
Fig. 5.
Protein labeling and nanodisc reconstitution for smFRET. SbPOR2b mutant
N181C/C536S/A552C containing two solvent accessible cysteines was labeled with
Cy3 and Cy5 maleimide mono-reactive dyes (GE Healthcare) according to estab-
lished protocols18. In brief, 1 mg SbPOR2b was incubated with 200 µM DTT at 4 °C
for 2 h. Cy3 and Cy5 solubilized in DMSO was added to POR and incubated over
night at 4 °C. A stoichiometric ratio of 1:2 Cy3/Cy5 was used for optimal labeling
conditions. Control samples labeled with one type of fluorophore were also
included. Samples with fluorophores were kept dark to prevent photobleaching.
Free dye was separated from labeled POR by size exclusion chromatography on
PD-10 desalting columns with Sephadex G-25 resin (Sigma Aldrich) equilibrated
with buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 20 mM cholate). Labeled
protein was reconstituted in lipid nanodiscs comprising membrane scaffold protein
MSP1E3D1 and a mixture of DLPC:DLPG:Biotinyl Cap PE:DiO (69.8:25:4:1.2
ratio) according to established protocols18,31. In brief, detergent solubilized POR
was mixed with nanodisc constituents, 5 mM DTT and 100 μM FAD and FMN.
The mixture was incubated on ice on a shaking platform for 1 h followed by
addition of biobeads and additional 4 h of incubation facilitate detergent removal.
Samples were centrifuged briefly to remove biobeads followed by centrifugation at
4000 x g and 5 °C for 10 min. Supernatant was collected and transferred to
eppendorf tubes. Purification of nanodiscs was achieved by size exclusion chro-
matography (SEC) (flow rate: 0.5 mL/min) on a preparative HPLC (Shimadzu)
equipped with a Superdex 200 Increase 10/300 GL column (Amersham Pharmacia
Biotech; diameter 10 mm; length 300 mm) using a mobile phase of 50 mM Tris-
HCl (pH 7.5), 100 mM NaCl. Elution of protein, Cy3 and Cy5 was continuously
monitored by absorbance at 280, 550 and 650 nm, respectively. Selected fractions of
nanodiscs containing POR were collected, flash frozen and stored at −80°C until
further use.
Surface preparation and nanodisc immobilization for smFRET. Dual-labeled
POR reconstituted in lipid nanodiscs was immobilized on a PLL-PEG functiona-
lized surface. The surfaces were prepared according to established protocols31,48. In
brief, glass coverslips were cleaned, dried under nitrogen flow and plasma etched
(Harrick Plasma Cleaner PDC-32G-2) for 5–10 min at 60 Pa. Immediately after
plasma etching, flow chambers were assembled using 6-channel sticky slides (Ibidi)
and each chamber was incubated with a 1:100 mixture of PLL-PEG-biotin/PLL-
PEG in HEPES buffer (pH 5.6) for at least 1 h. Chambers were flushed with 1 mL
buffer to remove excess PLL-PEG and afterwards incubated with 0.1 g/L Neu-
trAvidin for at least 10 min. The chambers were stored at 5 °C until further use.
Prior to each measurement, excess NeutrAvidin was removed by flushing each
chamber with ~1 mL buffer followed by incubation with lipid nanodisc for at
least 5 min to ensure immobilization. Excess nanodiscs were removed by flushing
with buffer.
Acquisition of smFRET data. All smFRET experiments were performed on a total
internal reflection fluorescence (TIRF) microscope (IX83, Olympus) equipped with
two EMCCD cameras (imagEM X2, Hamamatsu) and an oil immersion 100x
objective (UAPON 100XOTIRF, Olympus). Cy3 and Cy5 fluorophores were
excited using 532 nm and 640 nm solid state laser lines (Olympus), respectively. A
quad band filter cube was used to block the lasers in the emission pathway, while a
multichannel imaging system (DC2 two-channel system, Photometrics) was used
to split the signal into two channels. 582/75 nm and 700/75 nm band pass ET filters
were used to filter donor (Cy3) and acceptor (Cy5) emission, respectively. All
experiments were performed using ALEX methodology48,51 with 200 ms temporal
resolution. All experiments were done in imaging buffer (50 mM TRIS, 600 mM
NaCl, pH 7.9) with triplet quenchers (2 mM trolox, 2 mM para-nitrobenzyl alco-
hol, 2 mM cyclooctatetraene) and an oxygen scavenging system (1 U/mL PCD,
2.5 mM PCA) to avoid blinking and improve photostability of the fluorescent dyes.
Quantitative analysis of smFRET data. Quantitative image analysis and classi-
fication of smFRET traces was carried out using DeepFRET54, our recently pub-
lished methodology based on machine learning. Time-dependent signal and
background traces were extracted for each colocalized Cy3/Cy5 pair and classified
by the Deep Neural Network model encompassing features like signal/background
ratio, noisiness, photobleaching and stoichiometry. Extracted traces were sorted by
setting a user-defined quality threshold to ensure only traces corresponding to
single donor and acceptor fluorophores with anti-correlated signals were used for
further analysis.
To correct FRET values for spectral crosstalk, direct excitation and detection
efficiency, DeepFRET implements the method precisely outlined by Hellenkamp
et al.52 based on established methodology as first described by Lee et al.51. In brief,
we obtained α and δ correction factors for spectral crosstalk and direct excitation
by manual inspection of the traces. Afterwards, we obtained the β and γ factors
from FRET versus stoichiometry 2D histograms. The corrected FRET efficiencies
were converted to distances using a Cy3/Cy5 Förster radius of 56 Å.
The distributions of FRET values for each experimental condition were fitted
with a mixture of gaussians using unbinned likelihood fitting. Although FRET
values are not technically Gaussian distributed, it has in practice been shown to be
a robust method with little discrepancy16,47,48. The number of underlying states
(i.e., gaussians) was determined based on Bayesian Information Criterion (BIC).
Since BIC is highly sensitive to the number of data points and each experimental
condition had a different number of accepted FRET traces, the number of
underlying states was determined from the largest data set as well as all data
combined both resulting in five gaussians as the best model (Supplementary
Fig. 13). The fit outputs the mean, sigma and weight of each gaussian within the
gaussian mixture. Based on this, even though the distributions overlap, the actual
contribution of each state to the overall distribution is accurately extracted. Hidden
Markov modeling (HMM) was used to identify dynamic transitions48.
Simulation of FRET traces and cross-correlation analysis. Traces were gener-
ated based on a two-state hidden markov model (HMM) with a transition prob-
ability of 0.95 between FRET states at 0.3 and 0.7, respectively. 8% gaussian noise
was added to donor and acceptor intensities to simulate experimental uncertainty.
To mimic various temporal resolutions, traces were binned at 1, 5, 10, 20, 50 and
100 frames per bin effectively causing between 0.95 and 95 transitions on average
per bin at the various conditions. After binning, all traces were cut to a length of
200 frames with no bleaching to ensure equal amounts of data at different temporal
resolutions. The Pearson cross-correlation was calculated for donor and acceptor
intensities of each trace subsequent to binning.
Statistical analysis of in vitro activity data. The average and standard deviation
(SD) of at least three independent replicates were calculated followed by normal-
ization to the average and SD of at least three independent control measurements
without ligand. The effect of each ligand was reported as a percentage of the control
with error propagation. All uncertainties represent ±SD unless otherwise stated. P
values were calculated based on t-tests correcting for multiple comparisons, since
the effect of multiple ligands were compared to the same set of control measure-
ments. For each set of control experiments, a one-way ANOVA test was performed
to decide whether the effect of one or more ligands were significantly different from
the control (confidence level: p < 0.05). In case of a statistically significant differ-
ence, Tukey’s HSD test was used for pairwise comparison between each of the
ligands and the control to determine which of the ligands had a significant effect
while correcting for multiple comparisons. The level of significance as determined
by Tukey’s HSD test is marked by asterisk symbols on the corresponding bar charts
(*p < 0.05; **p < 0.01; ***p < 0.005).
Fitting of dose-response (IC50) curves. Dose-response curves from POR activity
assays were fitted using the Hill equation in order to determine the IC50 value:
f ðxÞ ¼ Aþ B A
1þ IC50x
 n
Here, A represents the starting point (no ligand), B represents the end point
(maximum response) and n represents the Hill coefficient. The Hill coefficient was
bounded to the interval [0,5] in the presence of rifampicin and cyclophosphamide.
Dhurrin IC50 values were extracted from lower concentrations only (solid lines in
Fig. 3B) as the effect is inverted at concentrations above 100–500 μM dependent on
the assay. This is not due to photophysical effects (Supplementary Fig. 7). The
activity loss at high dhurrin concentrations may indicate the presence of a feedback
loop where high dhurrin concentrations inhibit POR electron transferring activity.
This is especially important as POR is crucial for dhurrin formation and indicates a
self-regulatory cue inhibiting POR function when high concentrations of dhurrin
are produced. While the mechanism for this is unclear, it could originate from an
alternative binding site with lower affinity. Deciphering this, however, extends
beyond the scope of this work and is worth further investigation in future studies.
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